MRC1 and neoplasm: The systemic therapy only frequency was 41–64% according to primary tumour location, RAS-, BRAF-, and MMR-status, with a markedly variable mOS of 6–23 months, which cannot be explained by the minor differences in systemic therapy intensity in the subgroups.